Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Cancer of unknown primary, favourable subsets, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
Some favourable subsets rest on small series decades old.
Whether a tissue-of-origin classifier should ever override the clinical picture is unsettled.
Patients outside specialist centres are often given empirical chemotherapy without the subset review.
Biopsy material is frequently too small for the full immunohistochemistry panel and sequencing.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
Treat as node-positive breast cancer: axillary dissection, breast radiotherapy or mastectomy, systemic therapy by receptor status.
Treat as head and neck cancer: HPV and EBV testing, neck dissection or chemoradiotherapy with cisplatin.
Treat as extragonadal germ cell tumour with cisplatin-based combination chemotherapy.
Platinum-etoposide as for extrapulmonary neuroendocrine carcinoma; somatostatin analogues and radioligand therapy for well-differentiated tumours.
Treat as advanced ovarian cancer: cytoreductive surgery and carboplatin-paclitaxel with maintenance as indicated.